Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

Novo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market.

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy as a once-a-week injection in India ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...

礼来试验性药bimagrumab与诺和诺德Wegovy联用，48周减重22.1%，92.8%来自脂肪；单用Wegovy减重15.7%，脂肪减重占比71.8%。周一美股收盘，礼来公司股价一度涨近3.6%，随后回落收涨1%。

格隆汇6月23日｜研究显示，患者在使用诺和诺德减肥药Wegovy的同时，联合服用礼来的实验性药物bimagrumab，在减重的同时能够有效保持肌肉质量。据周一在芝加哥举行的美国糖尿病协会年会公布的结果，联合用药的患者在48周内体重下降了22.1%，其中92.8%为体脂减少。值得注意的是，bimagrumab单药组减去的100%体重均来自脂肪，且瘦体重增加了2.5%。

The drug is under distribution and will be in pharmacies by end of the month, said Vikrant Shrotriya, Novo Nordisk's India ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...